Amgen
AMGN
NZ$478.87
Share price
1.13%
Change (1 day)
-3.96%
Change (1 year)
Categories
The biotechnology company Amgen was founded in 1980 as AMGen. With approximately 20,000 employees, Amgen is one of the world's largest biotechnology companies with annual sales of approximately $ 24 billion in 2018.
Revenue for Amgen (AMGN)
Revenue in 2025 (TTM): NZ$57.55 Billion
According to Amgen's latest financial reports the company's current revenue (TTM 
) is NZ$56.28 Billion. In 2024 the company made a revenue of NZ$59.26 Billion an increase over the revenue in the year 2023 that were of NZ$44.57 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Amgen from 1996 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | NZ$57.55 B | -2.89% |
| 2024 | NZ$59.26 B | 32.95% |
| 2023 | NZ$44.57 B | 7.52% |
| 2022 | NZ$41.46 B | 9.01% |
| 2021 | NZ$38.03 B | 7.94% |
| 2020 | NZ$35.23 B | 1.58% |
| 2019 | NZ$34.68 B | -2.02% |
| 2018 | NZ$35.40 B | 10.04% |
| 2017 | NZ$32.17 B | -3.07% |
| 2016 | NZ$33.19 B | 4.87% |
| 2015 | NZ$31.65 B | 23.6% |
| 2014 | NZ$25.60 B | 12.67% |
| 2013 | NZ$22.72 B | 8.29% |
| 2012 | NZ$20.98 B | 5.12% |
| 2011 | NZ$19.96 B | 2.32% |
| 2010 | NZ$19.51 B | -3.21% |
| 2009 | NZ$20.15 B | -22.02% |
| 2008 | NZ$25.85 B | 34.07% |
| 2007 | NZ$19.28 B | -4.79% |
| 2006 | NZ$20.25 B | 11.37% |
| 2005 | NZ$18.18 B | 23% |
| 2004 | NZ$14.78 B | 15.03% |
| 2003 | NZ$12.85 B | 23.59% |
| 2002 | NZ$10.40 B | 9.11% |
| 2001 | NZ$9.53 B | 21.01% |
| 2000 | NZ$7.87 B | 28.47% |
| 1999 | NZ$6.13 B | 22.29% |
| 1998 | NZ$5.01 B | 24.04% |
| 1997 | NZ$4.04 B | 29.92% |
| 1996 | NZ$3.11 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | NZ$103.02 B | 83.04% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$78.57 B | 39.59% | 🇺🇸 USA |
 GlaxoSmithKline GSK | NZ$66.97 B | 19.00% | 🇬🇧 UK |
 Gilead Sciences GILD | NZ$47.39 B | -15.80% | 🇺🇸 USA |
 Biogen BIIB | NZ$16.19 B | -71.23% | 🇺🇸 USA |
 AbbVie ABBV | NZ$94.62 B | 68.10% | 🇺🇸 USA |
 Johnson & Johnson JNJ | NZ$147.34 B | 161.77% | 🇺🇸 USA |
 Illumina ILMN | NZ$7.15 B | -87.29% | 🇺🇸 USA |
 Eli Lilly LLY | NZ$80.82 B | 43.59% | 🇺🇸 USA |